Dealmaking Quarterly Statistics, Q3 2020
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2020
Executive Summary
During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.
You may also be interested in...
ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Medtronic Adds Avenu’s Percutaneous Fistula Technology
Avenu’s Ellipsys vascular access system is an ultrasound-guided catheter to create a durable arteriovenous fistula for patients undergoing dialysis.
Smith & Nephew Pays $240M For Integra’s Extremities Business
Integra is divesting its underperforming extremity orthopedics product portfolio to focus on its neurosurgery, surgical instrument and regenerative medicine businesses.